Items tagged with Treatment
TB pills most effective prior to, not after, food: research (post)
A team from National Institute for Research in Tuberculosis (NIRT) examined 25 TB patients in Chennai who consumed food just before they took their medication.
Prevention of hearing loss in patients with multidrug-resistant TB (post)
A correspondence published in The Lancet addresses the issue of prevention of hearing loss in patients with multidrug-resistant TB by using newer drugs bedaquiline or delamanid, and repurposed drugs linezolid and clofazimine, instead of an injectable agent.
Bedaquiline or delamanid for rifampin-resistant tuberculosis? (post)
A comment published in The Lancet Respiratory Medicine describes how to choose between bedaquiline and delamanid for an individual patient with rifampin-resistant TB, and notes, "tuberculosis programmes should make both bedaquiline and delamanid available. Although there are no efficacy data to guide the choice of one agent over the other, there are clinical scenarios that favour either bedaquiline or delamanid, and there are some patients who will need both."
Delamanid to be introduced in India (post)
New Delhi, Oct 4 - Concerned over the rising number of multidrug-resistant tuberculosis (MDR-TB) cases in the country, the health ministry will introduce a new drug in a “controlled manner”.
Oak Therapeutics announces results of bioequivalence study of company’s oral dissolvable strip for TB (post)
Results of in vivo study signifies completion of another critical milestone in company’s Phase I of NIAID contract* to develop ODS strip for anti-tuberculosis treatment option.
TB Alliance moves two novel TB drugs into human trials (post)
GUADALAJARA (10 October, 2017) — TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted “Investigative New Drug” status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing.
High completion rate for isoniazid-rifapentine in latent TB (post)
SAN DIEGO, October 08, 2017—Discontinuation rates for the 12-dose isoniazid-rifapentine (3HP) regimen are low, and the regimen could help effectively treat latent tuberculosis infection (LTBI), confirmed a post-marketing analysis reported at IDWeek 2017.
For latent TB, 3-month rifapentine + isoniazid may be favorable for some (post)
SAN DIEGO, October 08, 2017—Findings from a retrospective chart review revealed that 3 months of rifapentine + isoniazid using directly observed therapy (3HP) resulted in a higher completion rate and no loss of follow-up vs. treatment with the traditional 9 months of isoniazid (9H) for latent tuberculosis infection (LTBI).
New pathways for childhood TB treatment: Lessons from the STEP-TB project (post)
TB Alliance and Unitaid released a report, New pathways for childhood TB treatment: Lessons from the STEP-TB project, documenting how the STEP-TB project has reshaped the market for pediatric TB drugs by reducing barriers to entry, engaging in innovative industry collaboration to launch optimized products for children, and mobilizing strong demand. Since launching in 2015, these new medicines have begun to reach children around the world, setting a precedent for future action in the fight to end TB.
STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant TB (post)
Guadalajara, Mexico, 13 October 2017 - Preliminary results - released today at the 48th Union Conference on Lung Health - from Stage 1 of the STREAM randomised clinical trial show that the nine-month treatment regimen being tested achieved favourable outcomes in almost 80 percent of those treated.
Page 34 of 108 · Total posts: 0
←First 33 34 35 Last→